U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Triple-Negative Breast Carcinoma

MedGen UID:
1784796
•Concept ID:
C5446362
•
Neoplastic Process

Definition

Triple-negative breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Triple-Negative Breast Carcinoma

Professional guidelines

PubMed

Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies.
Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC
Biochem Pharmacol 2023 Jun;212:115545. Epub 2023 Apr 11 doi: 10.1016/j.bcp.2023.115545. PMID: 37044296
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Bianchini G, De Angelis C, Licata L, Gianni L
Nat Rev Clin Oncol 2022 Feb;19(2):91-113. Epub 2021 Nov 9 doi: 10.1038/s41571-021-00565-2. PMID: 34754128
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM
Cancer Cell 2019 Mar 18;35(3):428-440.e5. Epub 2019 Mar 7 doi: 10.1016/j.ccell.2019.02.001. PMID: 30853353

Recent clinical studies

Etiology

Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies.
Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC
Biochem Pharmacol 2023 Jun;212:115545. Epub 2023 Apr 11 doi: 10.1016/j.bcp.2023.115545. PMID: 37044296
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Bianchini G, De Angelis C, Licata L, Gianni L
Nat Rev Clin Oncol 2022 Feb;19(2):91-113. Epub 2021 Nov 9 doi: 10.1038/s41571-021-00565-2. PMID: 34754128
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC, Lin NU, Polyak K
Cancer Discov 2019 Feb;9(2):176-198. Epub 2019 Jan 24 doi: 10.1158/2159-8290.CD-18-1177. PMID: 30679171Free PMC Article
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M
N Engl J Med 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. PMID: 28564564
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Diagnosis

Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP
BMJ 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. PMID: 37253507
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y
J Hematol Oncol 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. PMID: 36038913Free PMC Article
Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
MacDonald I, Nixon NA, Khan OF
Curr Oncol 2022 Jul 7;29(7):4768-4778. doi: 10.3390/curroncol29070378. PMID: 35877238Free PMC Article
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM
J Natl Compr Canc Netw 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. PMID: 32259782
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Therapy

Towards targeting the breast cancer immune microenvironment.
Harris MA, Savas P, Virassamy B, O'Malley MMR, Kay J, Mueller SN, Mackay LK, Salgado R, Loi S
Nat Rev Cancer 2024 Aug;24(8):554-577. Epub 2024 Jul 5 doi: 10.1038/s41568-024-00714-6. PMID: 38969810
Best of the year: Advanced breast cancer in 2023.
Schlam I, Chavez-MacGregor M
Breast 2024 Apr;74:103677. Epub 2024 Feb 14 doi: 10.1016/j.breast.2024.103677. PMID: 38401422Free PMC Article
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM
J Natl Compr Canc Netw 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. PMID: 32259782
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators
N Engl J Med 2018 Nov 29;379(22):2108-2121. Epub 2018 Oct 20 doi: 10.1056/NEJMoa1809615. PMID: 30345906
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M
N Engl J Med 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. PMID: 28564564

Prognosis

Molecular Classification of Breast Cancer.
Roy M, Fowler AM, Ulaner GA, Mahajan A
PET Clin 2023 Oct;18(4):441-458. Epub 2023 May 31 doi: 10.1016/j.cpet.2023.04.002. PMID: 37268505
Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies.
Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC
Biochem Pharmacol 2023 Jun;212:115545. Epub 2023 Apr 11 doi: 10.1016/j.bcp.2023.115545. PMID: 37044296
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y
J Hematol Oncol 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. PMID: 36038913Free PMC Article
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M
N Engl J Med 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. PMID: 28564564
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Clinical prediction guides

Immunotherapy in Breast Cancer.
Dvir K, Giordano S, Leone JP
Int J Mol Sci 2024 Jul 9;25(14) doi: 10.3390/ijms25147517. PMID: 39062758Free PMC Article
Molecular Classification of Breast Cancer.
Roy M, Fowler AM, Ulaner GA, Mahajan A
PET Clin 2023 Oct;18(4):441-458. Epub 2023 May 31 doi: 10.1016/j.cpet.2023.04.002. PMID: 37268505
Updates on breast biomarkers.
Najjar S, Allison KH
Virchows Arch 2022 Jan;480(1):163-176. Epub 2022 Jan 14 doi: 10.1007/s00428-022-03267-x. PMID: 35029776
PI3K Inhibitors in Breast Cancer Therapy.
Ellis H, Ma CX
Curr Oncol Rep 2019 Dec 11;21(12):110. doi: 10.1007/s11912-019-0846-7. PMID: 31828441
An overview of triple-negative breast cancer.
Kumar P, Aggarwal R
Arch Gynecol Obstet 2016 Feb;293(2):247-69. Epub 2015 Sep 4 doi: 10.1007/s00404-015-3859-y. PMID: 26341644

Recent systematic reviews

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.
Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, Hu J, Wang D, Ding Y, Wang X, Li W, Chen Z
Mol Cancer 2024 Nov 29;23(1):266. doi: 10.1186/s12943-024-02176-8. PMID: 39614285Free PMC Article
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
Haiderali A, Huang M, Pan W, Akers KG, Maciel D, Frederickson AM
Future Oncol 2024;20(22):1587-1600. Epub 2024 Apr 10 doi: 10.2217/fon-2023-0301. PMID: 38597713Free PMC Article
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D
Cancer Treat Rev 2022 Dec;111:102468. Epub 2022 Sep 28 doi: 10.1016/j.ctrv.2022.102468. PMID: 36202026
Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M, Song J, Yang H, Jin F, Zheng A
Acta Oncol 2022 Sep;61(9):1105-1115. Epub 2022 Aug 8 doi: 10.1080/0284186X.2022.2106795. PMID: 35939538
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Diana A, Franzese E, Centonze S, Carlino F, Della Corte CM, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M
Curr Oncol Rep 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. PMID: 30128845

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...